Stock analysts at Northland Securities began coverage on shares of CryoLife, Inc. (NYSE:CRY) in a research note issued to investors on Monday. The brokerage set an “outperform” rating and a $23.50 price target on the stock. Northland Securities’ target price points to a potential upside of 21.45% from the company’s current price.
Several other brokerages have also recently issued reports on CRY. Zacks Investment Research raised CryoLife from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Monday, October 17th. Canaccord Genuity set a $24.00 target price on CryoLife and gave the company a “buy” rating in a research report on Thursday, October 27th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $18.42.
CryoLife (NYSE:CRY) remained flat at $19.35 during mid-day trading on Monday. 22,830 shares of the company’s stock were exchanged. The company has a market capitalization of $635.61 million, a price-to-earnings ratio of 58.81 and a beta of 1.26. CryoLife has a 52-week low of $8.94 and a 52-week high of $20.15. The stock has a 50 day moving average of $19.17 and a 200-day moving average of $16.62.
CryoLife (NYSE:CRY) last announced its earnings results on Wednesday, October 26th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.08. The business had revenue of $45.30 million for the quarter, compared to analysts’ expectations of $44.90 million. CryoLife had a return on equity of 8.37% and a net margin of 6.00%. The business’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 EPS. Equities analysts predict that CryoLife will post $0.45 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of CRY. Capital Research Global Investors acquired a new stake in CryoLife during the third quarter worth $36,530,000. BlackRock Fund Advisors boosted its stake in shares of CryoLife by 10.7% in the third quarter. BlackRock Fund Advisors now owns 2,062,381 shares of the company’s stock worth $36,236,000 after buying an additional 199,375 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of CryoLife by 4.2% in the second quarter. Vanguard Group Inc. now owns 1,306,807 shares of the company’s stock worth $15,433,000 after buying an additional 53,007 shares in the last quarter. Northern Trust Corp boosted its stake in shares of CryoLife by 0.4% in the third quarter. Northern Trust Corp now owns 1,046,011 shares of the company’s stock worth $18,379,000 after buying an additional 4,460 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its stake in shares of CryoLife by 18.5% in the second quarter. Macquarie Group Ltd. now owns 1,014,361 shares of the company’s stock worth $11,980,000 after buying an additional 158,177 shares in the last quarter. 66.34% of the stock is owned by hedge funds and other institutional investors.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with our FREE daily email newsletter.